Fennec's Record Quarter Has a Quiet Second Number
A 56% headline and a 30% EBITDA margin deserve the applause — but an 8% sequential crawl and a vanished Norgine update are the subtler story.
FENC · Earnings Call · 2026-11-12
The headline is 56%; the tell is 8%
Chief financial officer Robert Andrade opened the quarter with a flourish: “Fennec just reported the best commercial quarter in its history.” — Robert C. Andrade, Chief Financial Officer · 2026-11-12 Net product sales of $19.4 million were up roughly 56% year over year from $12.5 million, adjusted EBITDA hit a record $5.8 million (30% of net product sales, versus $2.0 million and 16% a year ago), EPS flipped to $0.12 from a $0.02 loss, and the balance sheet carries $48.7 million of cash with no debt. The operating leverage is genuine — Andrade's own framed it as "our EBITDA grew by $3 million on a revenue growth of $2.3 million," and the fundamentals agree that a fixed-cost base is now throwing off profit where it once threw off losses: operating income swung from a long stretch below zero to roughly $2 million on the back of a revenue line that went from essentially nothing to $18 million in the prior quarter. But the number a room full of analysts actually reached for was the sequential one. Revenue walked up $15 million in Q1, $18 million in Q2, and $19.4 million in Q3 — roughly a 20% sequential gain that decelerated to around 8%. The 56% year-over-year figure is partly a lap of a soft base. Chase Knickerbocker of Craig-Hallum put the tension bluntly: “Enrollments up 23%; completed infusions up 58%. Both of those were greater than the sequential change in revenue from Q2 to Q3. Can you just help us understand kind of why?” — Chase Knickerbocker, Analyst · 2026-11-12 Andrade's answer — infusion timing, and a revenue mix that blends academic, outpatient and select government patients — is honest, but it is also the explanation for why the funnel's leading indicators can sprint while the top line walks.That carryover claim is the company's answer to the deceleration, and it is not nothing — management says October was strong and treats Q4 visibility as unusually good. But a reader should hold it lightly: "strong visibility" is a verbal promise, and the sequential slope is the hard number.Entering the fourth quarter of 2026, we have the largest number of patients planned infusions, and planned vials being carried over from the third quarter. Importantly, we have strong visibility into the strength of our fourth quarter.